Jinzeng Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Jinzeng Wang has a total of 63 co-authors. Here are the top co-authors by number of shared publications:
- Haoran Mu
Department of Orthopedic Oncology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
3 shared publications - Yingqi Hua
Department of Orthopedic Oncology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China; Shanghai Bone Tumor Institution, Shanghai, China
3 shared publications Dongqing Zuo
Department of Orthopedic Oncology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China; Shanghai Bone Tumor Institution, Shanghai, China
2 shared publicationsHaoyu Wang
Institute for Data-Driven Tumor Immunology, Chongqing Medical University, Chongqing, China
2 shared publicationsHongsheng Wang
Department of Orthopedic Oncology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China; Shanghai Bone Tumor Institution, Shanghai, China
2 shared publications- Liu Yang
Department of Orthopedic Oncology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
2 shared publications
Latest Publications
- Open Access
- 27 February 2026
- Published by Elsevier in Cell Reports Medicine
- Vol. 7 (3) , 102644
Reconstruction of T cell infiltration in an osteosarcoma PDX-organoid interactive biobank for personalized immunotherapy
- 27 February 2026
- Published by Elsevier in Cell Reports Medicine
- Vol. 7 (3) , 102644
Open AccessReconstruction of T cell infiltration in an osteosarcoma PDX-organoid interactive biobank for personalized immunotherapy
- Open Access
- 10 December 2025
- Published by Springer Nature in npj Precision Oncology
- Vol. 10 (1)
Targeting high-risk MYC-overexpressed osteosarcoma with an Aurora kinase inhibitor:--results from a pilot umbrella trial
Osteosarcoma is a highly heterogeneous cancer, and molecular subtyping has the potential to increase diagnostic precision and facilitate targeted therapies. In our previous study, we classified osteosarcoma into four distinct subtypes. Here, we conducted a genomic subtype-guided pilot umbrella trial (ChiCTR2000036618, 2020/08/24) to evaluate the efficacy and safety of multiple precision therapies. Nineteen patients with refractory metastatic osteosarcoma were enrolled and stratified using whole-exome sequencing (WES) and immunohistochemistry (IHC). Patients were assigned to three arms: (A) PD-1 antibody plus gemcitabine and docetaxel; (B) PARP inhibitor combined with temozolomide; or (C) tinengotinib (TT-00420), a small-molecule aurora kinase inhibitor currently in clinical trials. The median progression-free survival and overall survival were 50 days (95% CI: 33–89) and 149 days (95% CI: 90–185). Tinengotinib has shown promising efficacy in our preclinical studies, suggesting its potential for clinical use, particularly in combination with immunotherapy. Additionally, we found that patients with MYC amplification presented increased tumor purity and ploidy, homologous recombination deficiency scores, and an immunosuppressive microenvironment. This study demonstrated the feasibility of using genomic molecular subtyping to guide the precise treatment of osteosarcoma. We also revealed that the abnormal genomic and transcriptomic profiles caused by MYC amplification could be suppressed by tinengotinib.
- 10 December 2025
- Published by Springer Nature in npj Precision Oncology
- Vol. 10 (1)
Open AccessTargeting high-risk MYC-overexpressed osteosarcoma with an Aurora kinase inhibitor:--results from a pilot umbrella trial
Osteosarcoma is a highly heterogeneous cancer, and molecular subtyping has the potential to increase diagnostic precision and facilitate targeted therapies. In our previous study, we classified osteosarcoma into four distinct subtypes. Here, we conducted a genomic subtype-guided pilot umbrella trial (ChiCTR2000036618, 2020/08/24) to evaluate the efficacy and safety of multiple precision therapies. Nineteen patients with refractory metastatic osteosarcoma were enrolled and stratified using whole-exome sequencing (WES) and immunohistochemistry (IHC). Patients were assigned to three arms: (A) PD-1 antibody plus gemcitabine and docetaxel; (B) PARP inhibitor combined with temozolomide; or (C) tinengotinib (TT-00420), a small-molecule aurora kinase inhibitor currently in clinical trials. The median progression-free survival and overall survival were 50 days (95% CI: 33–89) and 149 days (95% CI: 90–185). Tinengotinib has shown promising efficacy in our preclinical studies, suggesting its potential for clinical use, particularly in combination with immunotherapy. Additionally, we found that patients with MYC amplification presented increased tumor purity and ploidy, homologous recombination deficiency scores, and an immunosuppressive microenvironment. This study demonstrated the feasibility of using genomic molecular subtyping to guide the precise treatment of osteosarcoma. We also revealed that the abnormal genomic and transcriptomic profiles caused by MYC amplification could be suppressed by tinengotinib.
- Open Access
- 20 February 2025
- Published by Elsevier in Cell Reports Medicine
- Vol. 6 (3) , 101977
Methionine intervention induces PD-L1 expression to enhance the immune checkpoint therapy response in MTAP-deleted osteosarcoma
- 20 February 2025
- Published by Elsevier in Cell Reports Medicine
- Vol. 6 (3) , 101977
Open AccessMethionine intervention induces PD-L1 expression to enhance the immune checkpoint therapy response in MTAP-deleted osteosarcoma